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Folate is key in one-carbon metabolism, disruption of which can interfere with DNA synthesis, repair, and methylation. Efficient one-carbon
metabolism requires other B vitamins and the optimal activity of enzymes including 5,10-methylenetetrahydrofolate reductase (MTHFR).
We report a population-based case–control study of folate intake, related dietary factors and MTHFR polymorphisms (C677T, A1298C) and color-
ectal cancer in a population with relatively high colorectal cancer incidence and relatively low folate intake. A total of 264 cases with histologi-
cally confirmed incident colorectal cancer and 408 controls participated. There was no clear trend in risk with reported intakes of total, or dietary,
folate, riboflavin, vitamin B12 or vitamin B6, nor were there interactions between folate intake and the other B vitamins or alcohol. For C677T, risk
decreased with increasing variant alleles (multivariate OR for CT v. CC ¼ 0·77 (95% CI 0·52, 1·16); OR for TT v. CC ¼ 0·62 (95% CI 0·31,
1·24)), which, although not statistically significant, was consistent with previous studies. For A1298C, compared with AA subjects, CC subjects
had modest, non-significant, reduced risk (multivariate OR ¼ 0·81 (95% CI 0·45, 1·49)). There were significant interactions between total folate
and C677T (P¼0·029) and A1298C (P¼0·025), and total vitamin B6 and both polymorphisms (C677T, P¼0·016; A1298C, P¼0·033), although
the patterns observed differed from previous studies. Seen against the setting of low folate intake, the results suggest that the role of folate
metabolism in colorectal cancer aetiology may be more complex than previously thought. Investigation of particular folate vitamers (for example,
tetrahydrofolate, 5,10-methylenetetrahydrofolate) may help clarify carcinogenesis pathways.
Folate: MTHFR: Colorectal cancer: One-carbon metabolism
Folate, and its synthetic form, folic acid, is key in one-carbon
metabolism, the disruption of which can interfere with DNA
synthesis, repair and methylation. Low folate status or, more
generally, low dietary methyl status (a combination of
folate, methionine, alcohol and other B vitamins) may pro-
mote carcinogenesis. The mechanisms by which low folate
could increase risk of malignancy include: (1) DNA hypo-
methylation and inappropriate activation of oncogenes1; and/
or (2) uracil misincorporation during DNA repair and syn-
thesis, leading to DNA strand breaks, chromosome damage
and, eventually, malignant transformation2. Higher reported
folate intake has been associated with reduced colorectal
cancer risk3. However, most studies have been conducted in
populations where intake is relatively high, and a substantial
proportion comes in the form of folic acid, either from
supplements or through fortified foods; folic acid is more bio-
available than natural folates4.
Efficient one-carbon metabolism also requires riboflavin,
vitamin B6, vitamin B12 and methionine. This raises the possi-
bility that these factors, either on their own account, or by
acting together with folate, might influence colorectal cancer
risk. However, the available evidence is limited and/or incon-
sistent5.
One-carbon metabolism further requires the optimal activity
of multiple enzymes, including 5,10-methylenetetrahydrofo-
late reductase (MTHFR), which directs the folate pool towards
methylation or DNA repair. Several polymorphisms have been
reported in the MTHFR gene, but only two have been investi-
gated in relation to colorectal neoplasia – C677T and
A1298C5. The 677T variant lowers enzyme activity in vitro6
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and has been associated with decreased plasma folate and
vitamin B12 levels and raised homocysteine
7,8. In vitro studies
suggest that low folate status may be required for this poly-
morphism to affect enzyme activity in vivo9,10. The functional
impact of the A1298C polymorphism is less clear5,11. In vitro
enzyme activity appears to be reduced in homozygous variants
and compound heterozygotes10,12,13, but the in vivo effects
remain to be determined.
Most, but not all, previous studies have found reduced col-
orectal cancer risk in homozygotes for the variant C677T
allele5,14. A1298C has been less extensively investigated,
and results have been inconsistent5,15. The inconsistencies
may be due, in part, to differences in genotype distributions
and folate intakes between populations.
The Scottish diet is distinguished by low vegetable intake16.
This suggests folate levels may be relatively low, a view con-
firmed by the National Food Survey which revealed geo-
graphical variations in blood folate across Britain, with the
lowest levels in Scotland17. The high alcohol intake18 and
smoking prevalence19 may further compromise folate and,
more generally, methyl status in the Scottish population.
Furthermore, colorectal cancer incidence in Scotland is in
the upper quarter of rates observed worldwide20.
We undertook a population-based case–control study in
the north-east of Scotland to investigate whether intakes of
folate and related dietary factors, and MTHFR polymorphisms,
were associated with colorectal cancer risk in a population
with a relatively low folate intake.
Materials and methods
Ascertainment of cases and controls
Eligible cases were resident in the Grampian Health Board
region and diagnosed with a histological confirmed first pri-
mary invasive tumour of the colon or rectum between
September 1998 and February 2000. They were identified
each month from the computerised records of Aberdeen
Royal Infirmary pathology laboratory, which provides the cen-
tralised service for Grampian.
Controls were selected from the Grampian Community
Health Index, an inventory of everyone registered with a gen-
eral practitioner. The Grampian Community Health Index has
a high level of completeness for the Grampian population21.
Each month, a pool of potential controls was selected at
random, frequency matched to cases on age and sex. Individ-
uals who declined to take part were replaced.
The study was approved by the Joint Ethical Committee of
the University of Aberdeen and Grampian Health Board
(Scotland, UK). All participants gave informed consent.
Assessment of diet and other exposures
With the permission of their general practitioner, subjects
were recruited by post. They completed a questionnaire com-
prising a 150-item semi-quantitative FFQ22 plus questions on
a range of socio-demographic and lifestyle factors relevant to
colorectal cancer aetiology. The FFQ had been validated in
the local population23 and included questions on dietary
supplement use in the reference period (approximately 1
year before completion).
Genotyping
Subjects provided a mouthwash sample. DNA was extracted
from exfoliated buccal cells using the Elucigene CF12 proto-
col (Zeneca Diagnostics, Abingdon, Oxon, UK) and amplified
by PCR. The amplification products were digested with HinfI
for C677T7 and MboII for A1298C24. Resultant products were
separated by electrophoresis through 3% (Metaphorw, FMC
BioProducts) gels. Bands were visualised by ethidium bromide
staining and UV transillumination.
Analyses were blind to case–control status. Each batch
contained a negative (no template DNA) and two positive
controls. Analyses were repeated if either amplification or
digestion failed. Gels were double-read by two individuals
and assays repeated for any samples considered ambiguous.
Genotyping was also repeated, blind to the original results,
for a 10% random selection (n 67) of samples; no differ-
ences were found compared with the originally assigned
genotypes.
Statistical analysis
The dietary data were converted into estimated nutrient
intakes using the UK national food composition tables,
taking account of cereal fortification25. For seven subjects
(three cases and four controls) the FFQ was not completed
or was very incomplete. A further twelve subjects (six cases
and six controls) were excluded on the basis of implausible
total energy intakes (, 3347 kJ/d for men or , 2092 kJ/d
for women26 or more than three standard deviations above
mean intake in men and women separately). Protein intake
was used as a surrogate for methionine. Dietary intakes
were adjusted for total energy using the nutrient residual
method26. For folate, vitamin B6, vitamin B12 and riboflavin,
the primary analyses related to total intake, i.e. the sum of
dietary (energy adjusted) and supplement intakes; secondary
analyses related to dietary intake. Subjects were grouped
into intake tertiles (for alcohol) or quartiles (other variables),
based on the combined case and control distribution27, with
the baseline group comprising non-consumers (alcohol) or
the lowest quartile. For methyl content, the ‘low’ group com-
prised low total folate and protein (, median) and high
alcohol (upper two tertiles) and the ‘high’ group had high
total folate and protein ($ median) and low alcohol (no
intake or lowest tertile).
For C677T and A1298C, separate and compound geno-
type was assigned. Hardy–Weinberg equilibrium was
assessed in controls using Pearson’s x2. Association analyses
were done for individual genotypes, and combining carriers
of the variant alleles, taking homozygotes for the common
allele as the reference group. In addition, to explore the
impact of one variant in the absence of the other, risk esti-
mates were computed for (i) C677T genotype among
1298AA carriers and (ii) A1298C genotypes among
677CC carriers. Logistic regression was used to compute
adjusted and multivariate odds ratios (OR) and 95% CI in
Stata 8 (StataCorp LP, College Station, TX, USA). Adjusted
OR were adjusted for sex, age and, for the dietary variables,
total energy intake. Multivariate OR were further adjusted
for potential confounders; factors which made a significant
contribution (likelihood ratio test P,0·1) were retained in
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the model. Trend tests28 were used to investigate dose–
response across dietary quantiles or by number of variant
alleles. Effect modification was explored by computing OR
for combinations of (i) intake variables and (ii) intake and
genotype. The test for interaction was the change in
deviance (22 £ log likelihood) between a main-effects
model and one including a cross-product term. All multi-
variate models were checked for adequate fit29.
Results
A total of 264 cases (62% of those eligible) and 408 controls
(61%) participated. Of the 264 cases, 189 cases had colon
cancer and seventy-five rectal cancer (Table 1). Cases
tended to be older than controls, and a higher proportion
were men.
Median total folate intake was 299·7 (interquartile range
263·9–348·6) mg/d (Table 2). Median dietary folate was 295
(interquartile range 261–332) mg/d. Of the subjects, 9·5%
(thirty-eight controls (9·4%) and twenty-five cases (9·6%))
reported taking a supplement that contained folic acid. The
majority (fifty-three out of sixty-three) took supplements that
included 200mg folic acid.
For total folate intake, the multivariate OR exceeded unity
for quartiles 2–4, but there was no clear trend (Table 2).
A similar pattern was observed for total riboflavin. There
was a borderline significant association between protein
intake and risk (global P¼0·055; P(linear trend)¼0·066),
due to a one-third reduction in risk in the highest intake
group. Compared with non-drinkers, disease risk was slightly,
but non-significantly, raised for all categories of alcohol
intake. The association was strongest in males (multivariate
OR for T1 v. none ¼ 1·58 (95% CI 0·60, 4·15); OR for T2
v. none ¼ 1·57 (95% CI 0·65, 3·80); OR for T3 v. none
¼ 1·72 (95% CI 0·73, 4·04)). There was a suggestion of
increasing risk with decreasing dietary methyl content,
although the risk estimates were not statistically significant.
There were no associations between total vitamin B12 or vita-
min B6 intakes and colorectal cancer.
Results of analyses restricted to dietary intake of folate,
vitamin B12, vitamin B6 and riboflavin were similar to those
for total intake, with slightly attenuated risk estimates (data
not shown).
There was no evidence of interactions between total
folate intake and total intake of vitamin B12, vitamin B6 or
riboflavin, nor did particular combinations of alcohol and
total folate influence risk (data not shown). Results were
unchanged when analyses were repeated for dietary intake
(data not shown).
The C677T genotype distribution among controls con-
formed with Hardy–Weinberg equilibrium (x21 ¼ 0·00;
P¼0·999), but the A1298C distribution did not (x21 ¼ 6·25;
P,0·05); there was an excess of homozygous subjects (AA
and CC) and a deficit of heterozygotes. For C677T, risk
decreased with increasing number of variant alleles (multivari-
ate OR for CT v. CC ¼ 0·77 (95% CI 0·52, 1·16); OR for TT
v. CC ¼ 0·62 (95% CI 0·31, 1·24)) but not significantly
(P(linear trend)¼0·103; Table 3). For A1298C, the risk for
homozygous variant subjects was modestly, but not signifi-
cantly, reduced (OR for CC v. AA ¼ 0·81 (95% CI 0·45,
1·49)). As regards compound genotype, no subjects were
homozygous for both variants, while four cases (1·7%) and
eleven controls (2·8%) had three variant alleles. Compared
with those with no variant alleles, individuals who were
double heterozygous (OR ¼ 0·85 (95% CI 0·41, 1·75)) or
homozygous variant (OR ¼ 0·71 (95% CI 0·35, 1·45)) had
slightly reduced risk. Among individuals who were 1298AA,
multivariate OR for the C677T genotypes were: 1·00, 0·82
(95%CI 0·40, 1·67) and 0·77 (95% CI 0·30, 1·93). Multivari-
ate risk estimates for the A1298C genotypes among individ-
uals who were 677CC were: 1·00, 1·41 (95% CI 0·67, 2·96)
and 0·75 (95% CI 0·33, 1·73).
There was a significant interaction between C677T and total
folate (Table 4; P(interaction)¼0·029). Compared with CC
individuals with low (, median) intake, risk was significantly
reduced in carriers of the variant allele with low intake (OR
¼ 0·47 (95% CI 0·27, 0·83)), with a less pronounced risk
reduction in those with high intake. A significant interaction
was found between total vitamin B6 intake and C677T
(P(interaction)¼0·016), which followed a similar pattern to
that for total folate. Repeating the analyses for dietary folate
and vitamin B6 gave less pronounced risk estimates (data
not shown).
There was a suggestion that C677T modified the associ-
ations between protein and alcohol intakes and colorectal
cancer, although the tests for interaction were not statistically
Table 1. Characteristics of study participants by case–control status
(Numbers and percentages)
Controls Cases
Factor n %* n %*
Sex
Female 198 48·5 114 43·2
Male 210 51·5 150 56·8
Age (years)†
, 55 101 24·8 23 8·7
55–64 127 31·1 60 22·7
65–74 111 27·2 91 34·5
75 and older 69 16·9 90 34·1
Tumour location
Colon 189 71·6
Rectum 75 28·4
First-degree family history of colorectal cancer
No 371 91·1 214 81·4
Yes 36 8·9 49 18·6
Social class‡
I and II (non-manual) 168 42·6 92 36·2
III (skilled manual) 158 40·1 118 46·5
IV and V (unskilled manual) 68 17·3 44 17·3
Country of birth
UK or Ireland 385 96·3 252 98·0
Elsewhere 15 3·7 5 2·0
Smoking status§
Never smoked 161 40·4 106 41·3
Ex-smoker 164 41·1 114 44·4
Current smoker 74 18·6 37 14·4
* Percentage of those subjects with complete data for a particular factor.
† Age at diagnosis for cases and at pseudo date of diagnosis for controls (middle of
month in which cases diagnosed).
‡ Based on occupation at time questionnaire completed, or last occupation before
retirement: for men and single women, based on own occupation; for women
who were married, living as married, or widowed, based on occupation of hus-
band or partner.
§ At approximately 1 year before the completion of the questionnaire.
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significant. There were no interactions between C677T and
either vitamin B12 or riboflavin.
A significant interaction was observed between total folate
and A1298C (Table 5; P(interaction)¼0·025). The group at
lowest risk comprised homozygotes for the wild-type allele
with low intake. Compared with this group, those with the
AC/CC genotype and low intake or AA genotype and
high intake had significantly raised risk (OR ¼ 1·75 (95%
CI 1·00, 3·10) and OR ¼ 1·91 (95% CI 1·05, 3·50) respect-
ively). Similar patterns were apparent for dietary folate (data
not shown; P(interaction) ¼ 0·060) and total (Table 5;
P(interaction)¼0·033) and dietary vitamin B6 (data not
shown; P(interaction)¼0·053). A1298C did not modify the
relationships between colorectal cancer and vitamin B12 or
Table 2. Association between intake variables and colorectal cancer
(Numbers and percentages of subjects, P values for likelihood ratio tests, odds ratios and 95 % confidence intervals)
Controls Cases
n % n % Adjusted OR* 95 % CI Multivariate OR† 95 % CI
Total folate (mg/d)
Q1, # 263·9 102 25·6 62 24·3 1·0 – 1·0 –
Q2, 264·0–299·6 90 22·6 73 28·6 1·66 1·04, 2·66 1·87 1·08, 3·22
Q3, 299·7–348·5 97 24·4 66 25·9 1·48 0·92, 2·38 1·77 1·01, 3·08
Q4, $ 348·6 109 27·4 54 21·2 1·05 0·65, 1·70 1·37 0·79, 2·36
Global P 0·087 0·098
Trend P 0·982 0·402
Total vitamin B12 (mg/d)
Q1, # 5·25 100 25·1 64 25·1 1·0 – 1·0 –
Q2, 5·26–6·45 97 24·4 66 25·9 1·21 0·75, 1·94 1·21 0·71, 2·05
Q3, 6·46–7·97 99 24·9 64 25·1 1·07 0·67, 1·72 1·21 0·71, 2·04
Q4, $ 7·98 102 25·6 61 23·9 0·77 0·63, 1·63 0·95 0·56, 1·62
Global P 0·858 0·729
Trend P 0·258 0·866
Total vitamin B6 (mg/d)
Q1, # 2·29 94 23·6 70 27·5 1·0 – 1·0 –
Q2, 2·30–2·61 97 24·4 66 25·9 1·17 0·73, 1·87 1·03 0·60, 1·77
Q3, 2·62–3·03 103 25·9 60 23·5 1·08 0·67, 1·74 1·24 0·73, 2·12
Q4, $ 3·04 104 26·1 59 23·1 0·99 0·62, 1·59 1·07 0·63, 1·81
Global P 0·894 0·862
Trend P 0·891 0·661
Total riboflavin (mg/d)
Q1, # 1·87 106 26·6 58 22·8 1·0 – 1·0 –
Q2, 1·88–2·13 96 24·1 67 26·3 1·36 0·84, 2·18 1·43 0·83, 2·46
Q3, 2·14–2·48 98 24·6 65 25·5 1·30 0·81, 2·08 1·63 0·96, 2·79
Q4, $ 2·49 98 24·6 65 25·5 1·32 0·82, 2·12 1·44 0·83, 2·47
Global P 0·545 0·312
Trend P 0·313 0·166
Protein (g/d)‡
Q1, # 85·2 97 24·4 65 25·5 1·0 – 1·0 –
Q2, 85·3–93·5 81 20·4 80 31·4 1·61 1·00, 2·58 1·43 0·84, 2·43
Q3, 93·6–102·9 105 26·4 61 23·9 1·07 0·67, 1·73 0·92 0·54, 1·57
Q4, $ 103·0 115 28·9 49 19·2 0·78 0·48, 1·26 0·67 0·39, 1·16
Global P 0·026 0·055
Trend P 0·143 0·066
Alcohol (g/d)
None 77 19·4 51 20·0 1·0 – 1·0 –
T1, # 3·91 103 25·9 72 28·2 1·02 0·61, 1·70 1·22 0·66, 2·23
T2, 3·94–11·99 106 26·6 69 27·1 1·20 0·73, 1·97 1·26 0·70, 2·25
T3, $ 12·00 112 28·1 63 24·7 1·14 0·67, 1·93 1·22 0·67, 2·23
Global P 0·876 0·877
Trend P 0·510 0·553
Methyl content§
High 57 14·3 27 10·6 1·0 – 1·0 –
Intermediate 286 71·9 188 73·7 1·45 0·86, 2·43 1·36 0·76, 2·40
Low 55 13·8 40 15·7 1·59 0·83, 3·06 1·54 0·75, 3·19
Global P 0·306 0·474
Trend P 0·175 0·250
Q, quartile; T, tertile; NSAID, non-steroidal anti-inflammatory drugs.
* Adjusted for age, sex and total energy.
† All models adjusted for sex, age, total energy, physical activity, family history of colorectal cancer, regular use of any NSAID, sex £ NSAID inter-
action term; model for protein also adjusted for type of dietary supplement; model for alcohol also adjusted for type of dietary supplement and
protein.
‡ Protein from food only.
§ High methyl content is high total folate, high protein and either no alcohol intake or intake in T1; low methyl status is low total folate, low protein and
alcohol in upper two tertiles; intermediate is all other combinations of total folate, protein and alcohol. High folate or protein is intake in upper two
quartiles; low folate or protein is intake in lower two quartiles.
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riboflavin, either for total (Table 5) or dietary intake (data
not shown). There were no significant interactions between
A1298C and protein or alcohol.
Discussion
Strengths and limitations
The major strength of the study was the population basis, with
both cases and control recruited from population-based
sampling frames. The participation rate was similar to another
UK study in which contact was made by post30. Other than
refusal, the main reasons for non-participation among cases
were death (n 37; 8·7% of those eligible) or general prac-
titioner refusal (n 15; 3·5%), primarily because subjects
were deemed to be too ill to approach. For controls, the gen-
eral practitioner refused permission to approach sixteen indi-
viduals and a further eight had died (3·6% in total). Eligible
male cases were significantly more likely to participate than
females; controls resident in urban areas were significantly
less likely to take part31. Deprivation category of residence
was not significantly associated with participation among
either cases or controls. Analysis of known colorectal cancer
risk factors resulted in associations consistent with previous
evidence32.
Of the controls, 12% were 677TT homozygotes, consistent
with the frequency in other white and northern European
populations33. Of the controls, 15% carried the 1298 CC
genotype, slightly higher than the prevalence in most Euro-
pean studies5, but consistent with another study in the
same area (18% CC)34. The A1298C genotype frequencies
were not in Hardy–Weinberg equilibrium. Since subjects
were unaware of the study hypotheses or their genotype,
differential participation by genotype seems unlikely. More-
over, the genotyping followed rigorous quality-control
measures, which should help guard against systematic
errors35. Other potential explanations for a departure from
Hardy–Weinberg equilibrium include non-random mating,
genetic drift and chance.
The FFQ was developed and extensively validated in the
local area. For folate, alcohol and riboflavin, high levels of
agreement (rank correlation coefficients 0·55–0·79) were
found when comparing questionnaire responses with 4 d
weighed records23.
The case–control design is potentially susceptible to the
effects of recall bias in the assessment of lifestyle (but not
Table 3. Association between methylenetetrahydrofolate reductase (MTHFR) genotype and colorectal cancer
(Numbers and percentages of subjects, P values for likelihood ratio tests, odds ratios and 95 % confidence intervals)
Controls Cases
n % n % Adjusted OR* 95 % CI Multivariate OR† 95 % CI
C677T‡
Homozygous wild type (CC) 170 43·2 117 46·6 1·0 – 1·0 –
Heterozygous (CT) 177 44·9 111 44·2 0·91 0·64, 1·29 0·77 0·52, 1·16
Homozygous variant (TT) 47 11·9 23 9·2 0·75 0·42, 1·34 0·62 0·31, 1·24
Global P 0·603 0·264
Trend P 0·329 0·103
Heterozygous/homozygous variant (CT/TT)§ 224 56·9 134 53·4 0·88 0·63, 1·22 0·75 0·51, 1·09
Global P 0·441 0·134
A1298C k
Homozygous wild type (AA) 177 44·9 105 42·9 1·0 – 1·0 –
Heterozygous (AC) 157 39·9 111 45·3 1·18 0·82, 1·69 1·21 0·80, 1·84
Homozygous variant (CC) 60 15·2 29 11·8 0·67 0·39, 1·13 0·81 0·45, 1·49
Global P 0·100 0·375
Trend P 0·391 0·843
Heterozygous/homozygous variant (AC/CC)§ 217 55·1 140 57·1 1·03 0·73, 1·44 1·10 0·72, 1·63
Global P 0·879 0·632
Compound genotype{
Homozygous wild type (CC and AA) 43 11·1 26 10·7 1·0 – 1·0 –
Single heterozygous (CT or AC) 166 42·9 117 48·4 1·21 0·68, 2·13 1·08 0·57, 2·06
Double heterozygous (CT and AC) 74 19·1 48 19·8 1·02 0·54, 1·93 0·85 0·41, 1·75
Homozygous variant (TT or CC) 104 26·9 51 21·1 0·74 0·40, 1·38 0·71 0·35, 1·45
Global P 0·176 0·412
Trend P 0·076 0·129
Up to one variant allele** 209 54·0 143 59·1 1·0 – 1·0 –
Two or more variant alleles†† 178 46·0 99 40·9 0·74 0·52, 1·04 0·73 0·49, 1·08
Global P 0·078 0·115
NSAID, non-steroidal anti-inflammatory drugs.
* Adjusted for age and sex.
† Adjusted for sex, age, family history of colorectal cancer, physical activity, regular use of any NSAID, sex £ NSAID interaction term, total energy intake and type of dietary
supplements.
‡ Three cases did not provide a mouthwash sample; genotyping failed for ten cases and fourteen controls.
§ OR for carriers of variant allele v. homozygous wild-types.
kThree cases did not provide a mouthwash sample; genotyping failed for sixteen cases and fourteen controls.
{Three cases did not provide a mouthwash sample; compound genotype could not be assigned for nineteen cases and twenty-one controls because genotyping for either
C677T or A1298C had failed.
** Includes homozygous wild type for both polymorphisms or heterozygote for either polymorphism.
†† Includes heterozygotes for both polymorphisms or homozygous variant for either; OR for two or more variant alleles v. zero or one variant allele.
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genetic) risk factors. Other than this, the main limitation was
limited power both for main effects and, in particular, for
interactions. As regards main effects, for a genetic variant
occurring in 12% of the population (i.e. MTHFR TT) the
study had 80% power to detect an OR of 0·45 or less
(a ¼ 0·05; two-sided test); this OR is in the region of the
risk estimates reported in previous studies36. It should be
borne in mind that a relatively large number of statistical
tests were conducted, and a proportion of positive results
would be expected by chance.
Ethnic group was not assessed, but only 3% of subjects
were born outside the UK or Ireland (78% born in Scotland;
17% elsewhere in the UK or Ireland). In the 2001 census
for Scotland, 98% of the population described themselves as
‘white’ (Scottish, British, Irish or other) and 2% as south-
east Asian, Chinese or black37. Thus it seems unlikely that
the results were adversely affected by population stratification,
which needs to be quite extreme to have a major impact38.
Folate and other intake variables
Unlike most previous studies3, we did not find an inverse
relationship between total folate intake and colorectal
cancer. In contrast, compared with the lowest intake quartile,
risk estimates for the other quartiles exceeded unity, and
followed a bell-shaped pattern. A similar pattern has been
reported between plasma folate and colorectal cancer in a pro-
spective study from Sweden39. When our analysis was
restricted to subjects who did not use folic acid-containing
supplements, the pattern persisted (multivariate OR: 1·0,
1·86 (95% CI 1·07, 3·22), 1·82 (95% CI 1·03, 3·19) and
0·96 (95% CI 0·51, 1·79)). Although some previous studies
have found the inverse relationship to be stronger for colon
than rectal tumours40,41, when we stratified by site, there
was no clear evidence of a trend with colon or rectal cancer.
Although there may be substantial error in assessment of diet-
ary folate intakes42 and supplement use43, the resulting mis-
classification is most probably random, and would be
unlikely to produce the observed result.
In further analyses, in women we found a modest, albeit
non-significant, reduced risk in the highest total folate group
(age- and sex-adjusted OR for quartile 4 v. quartile 1 ¼ 0·73
(95% CI 0·35, 1·52)). Several other case–control studies
found that the association between colorectal neoplasia and
folate (as intake or from supplements) was only evident, or
was stronger, amongst females44–48. Folic acid supplement
use is reported to be higher in women49. In the present
study, 11·6% of females and 7·6% of males used folic acid-
containing supplements. These findings raise the possibility
that folate status (or bioavailable folate, at least) may be
Table 4. Interactions between methylenetetrahydrofolate reductase (MTHFR) C677T genotype and dietary variables*
(Odds ratios, 95 % confidence intervals, and P values for tests for interaction)
C677T genotype. . . CC CT/TT CC CT/TT
Dietary factor Adjusted OR† 95 % CI Adjusted OR† 95 % CI Multivariate OR‡ 95 % CI Multivariate OR‡ 95 % CI
Total folate
Low 1·0 – 0·61 0·37, 0·99 1·0 – 0·47 0·27, 0·83
High 0·69 0·41, 1·14 0·87 0·41, 1·14 0·75 0·43, 1·32 0·84 0·49, 1·43
P(interaction) 0·037 0·029
Total vitamin B12
Low 1·0 – 1·07 0·67, 1·73 1·0 – 0·89 0·52, 1·52
High 1·22 0·74, 2·02 0·87 0·54, 1·39 1·21 0·70, 2·11 0·75 0·43, 1·28
P(interaction) 0·233 0·347
Total vitamin B6
Low 1·0 – 0·62 0·38, 1·00 1·0 – 0·45 0·26, 0·79
High 0·68 0·41, 1·12 0·84 0·53, 1·35 0·71 0·41, 1·24 0·83 0·49, 1·39
P(interaction) 0·046 0·016
Total riboflavin
Low 1·0 – 0·84 0·51, 1·36 1·0 – 0·64 0·36, 1·12
High 1·13 0·68, 1·87 1·03 0·63, 1·67 1·19 0·68, 2·09 1·01 0·59, 1·74
P(interaction) 0·805 0·472
Protein
Low 1·0 – 1·07 0·66, 1·71 1·0 – 0·87 0·51, 1·48
High 0·97 0·59, 1·59 0·69 0·43, 1·12 0·88 0·50, 1·53 0·55 0·32, 0·97
P(interaction) 0·249 0·419
Alcohol
Low 1·0 – 0·65 0·40, 1·07 1·0 – 0·55 0·31, 0·98
High 0·79 0·47, 1·33 0·91 0·55, 1·50 0·76 0·42, 1·38 0·73 0·40, 1·32
P(interaction) 0·106 0·16
Methyl content
High or intermediate 1·0 – 0·86 0·60, 1·25 1·0 – 0·73 0·48, 1·11
Low 1·01 0·51, 2·00 0·93 0·46, 1·89 1·02 0·47, 2·20 0·89 0·40, 1·99
P(interaction) 0·902 0·748
NSAID, non-steroidal anti-inflammatory drugs.
* Folate, vitamin B12, vitamin B6, riboflavin and protein categorised at median intake; low alcohol intake is no intake or lowest tertile while high intake is intake in upper two ter-
tiles; high methyl content is high total folate, high protein and either no alcohol intake or intake in first tertile, low methyl status is low total folate, low protein and alcohol in
upper two tertiles, intermediate is all other combinations of total folate, protein and alcohol; protein based on intake from food sources.
† Adjusted for age, sex and total energy intake.
‡ All models adjusted for age, sex, total energy intake, family history of colorectal cancer, physical activity, regular use of any NSAID; model for protein also adjusted for type of
dietary supplements; models for alcohol and methyl content also adjusted for type of dietary supplements and sex £ NSAID interaction term.
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higher for females than males for the same intake; we are not,
however, aware of any evidence confirming this. There may
also be a differential effect by sex on folate status of other fac-
tors influencing dietary methyl content. For example, men are
more likely to drink alcohol, and to consume greater quan-
tities, than women48; in the present study, 74% of females
and 86% of males consumed alcohol. Similarly, methionine
intake can be very different, possibly because men are likely
to eat greater quantities of red meat50. Alternatively, folate
intake estimates among women may be subject to less
measurement error. In the validation of the FFQ used in the
present study, for most nutrients the agreement between ques-
tionnaire estimates and weighed records was higher for
females than males23.
The median dietary folate intake among controls (295mg/d)
was close to population estimates (average intake from food
and drink 274mg/d51). In the USA, by contrast, a large pro-
portion of the population meets the recommended intake of
400mg/d52. The proportion of controls taking folic acid-con-
taining supplements (, 10%) is typical of the UK popu-
lation53, but considerably lower than in the USA48,49,54. The
range of total intake in the present study was relatively
narrow; cut-off points for the lowest and highest quartiles
were 264 and 349mg/d. This contrasts with several previous
studies in which the cut-off point for the highest quantile
was . 600mg/d50,55–57. Moreover, in most previous studies,
including those where average intake was lower than in the
USA58,59, there was greater variability in intake than in the
present study. It is noteworthy that in the prospective study
in Sweden which reported a bell-shaped relationship between
plasma folate and colorectal cancer39 – similar to our finding
for folate intake – the plasma folate concentrations were con-
siderably lower than in prospective studies from the USA that
found inverse relationships with plasma or serum folate36,56.
Van Guelpen et al. concluded that the low folate status of
their study population may have precluded detection of a pro-
tective effect of high plasma folate concentrations39. A similar
conclusion holds for the present study (i.e. the generally low
intake, and narrow range, meant that a protective effect of
higher intakes could not be found). Further, in view of the
weight of evidence in this area, it seems most likely that the
increased risk observed for intermediate intakes is due to
chance.
The lack of statistical interaction between folate and alcohol
is compatible with most previous studies57–60. Although some
studies have suggested that the risk reduction associated with
Table 5. Interactions between methylenetetrahydrofolate reductase (MTHFR) A1298C genotype and dietary variables*
(Odds ratios, 95 % confidence intervals, and P values for tests for interaction)
A1298C genotype. . . AA AC/CC AA AC/CC
Dietary factor Adjusted OR† 95 % CI Adjusted OR† 95 % CI Multivariate OR‡ 95 % CI Multivariate OR‡ 95 % CI
Total folate
Low 1·0 – 1·70 1·04, 2·78 1·0 – 1·75 1·00, 3·10
High 1·62 0·96, 2·73 1·07 0·65, 1·78 1·91 1·05, 3·50 1·37 0·78, 2·41
P(interaction) 0·007 0·025
Total vitamin B12
Low 1·0 – 0·98 0·60, 1·60 1·0 – 1·09 0·63, 1·89
High 0·89 0·53, 1·49 1·03 0·63, 1·66 1·01 0·56, 1·83 1·14 0·66, 1·96
P(interaction) 0·64 0·943
Total vitamin B6
Low 1·0 – 1·43 0·88, 2·32 1·0 – 1·71 0·97, 3·01
High 1·30 0·77, 2·19 1·03 0·63, 1·68 1·82 0·99, 3·33 1·32 0·76, 2·29
P(interaction) 0·092 0·033
Total riboflavin
Low 1·0 – 1·04 0·63, 1·70 1·0 – 1·11 0·63, 1·95
High 1·14 0·68, 1·91 1·22 0·76, 1·95 1·42 0·78, 2·58 1·49 0·87, 2·54
P(interaction) 0·950 0·891
Protein
Low 1·0 – 0·87 0·54, 1·41 1·0 – 1·28 0·74, 2·22
High 0·58 0·34, 0·98 0·78 0·49, 1·26 0·82 0·45, 1·52 0·81 0·47, 1·39
P(interaction) 0·216 0·518
Alcohol
Low 1·0 – 1·44 0·88, 2·37 1·0 – 1·55 0·87, 2·76
High 1·50 0·87, 2·58 1·20 0·72, 2·01 1·54 0·82, 2·89 1·25 0·69, 2·25
P(interaction) 0·674 0·106
Methyl content
High or intermediate 1·0 – 1·06 0·73, 1·54 1·0 – 1·02 0·67, 1·55
Low 1·15 0·52, 2·53 1·23 0·65, 2·30 1·11 0·45, 2·74 1·46 0·72, 2·95
P(interaction) 0·986 0·658
NSAID, non-steroidal anti-inflammatory drugs.
* Folate, vitamin B12, vitamin B6, riboflavin and protein categorised at median intake; low alcohol intake is no intake or lowest tertile while high intake is intake in upper two ter-
tiles; high methyl content is high total folate, high protein and either no alcohol intake or intake in first tertile, low methyl content is low total folate, low protein and alcohol in
upper two tertiles, intermediate is all other combinations of total folate, protein and alcohol; protein based on intake from food sources.
† Adjusted for age, sex and total energy intake.
‡ All models (except methyl content) adjusted for sex, age, total energy, family history of colorectal cancer, physical activity, regular use of any NSAID and sex £ NSAID inter-
action term; models for protein and alcohol also adjusted for type of dietary supplements; model for methyl content adjusted for sex, age, total energy, family history of
colorectal cancer, physical activity, regular use of any NSAID and type of dietary supplements.
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high folate intake was confined to those with low methionine
intake55,59, we found no interaction between folate and protein
(as a marker for methionine). There is tension in the previous
evidence, however, in that the pattern of the folate–methion-
ine interaction is not consistent with what would be expected
on the basis of the low-methyl diet hypothesis: according to
this, the combination of low intakes of folate and methionine
together with high alcohol should increase disease risk. The
modest raised risk we observed for intermediate and low diet-
ary methyl content is broadly consistent with previous
studies48,50,58,60. The extent to which the effect of the
‘methyl diet’ on disease risk exceeds that of folate alone
remains unclear, however.
Effects of genotype
In most previous studies, carriers of three variant alleles, if they
have occurred at all, have been rare5. Our frequencies of 2·8%
among controls and 1·7% among cases are quite high but are,
of course, based on very small numbers of individuals. The
high frequency, which appears to occur mainly in UK and
Canadian populations, may be due to a founder effect61.
The moderate risk reduction, and dose–response, associated
with the 677T allele, although not statistically significant, is
compatible with most previous studies5,14. As regards
A1298C, eight of eleven studies found lower risk for the
variant allele15, although not all reached significance and an
effect was not seen in all subgroups. Our modest, non-signifi-
cant, reduced risk in CC subjects is consistent with this.
In common with previous investigators36,62,63, we found a
significant interaction between folate and C677T. However,
the pattern of interaction differed from that reported pre-
viously due, in part, to differences in the folate main effect.
In addition, for reasons of statistical power, we combined
CT and TT genotypes in the analysis. This would have con-
cealed the low risk in TT subjects with high folate (or dietary
methyl content) that has been reported elsewhere36,62,64.
Although we observed a significant folate–A1298C inter-
action, previous studies have been inconsistent54,63,65. There
is linkage disequilibrium between C677T and A1298C. In the
present study, sixty of the sixty-eight individuals with the
677TT genotype also carried 1298AA, while seventy-nine of
the eighty-seven who were 1298CC also carried 677CC.
This meant that there was considerable overlap between the
sub-groups at lowest risk in the two interaction analyses
(C677T: low folate and CT/TT genotype; A1298C: low
folate and AA genotype), which explains, in part, the different
patterns of interaction observed for the two polymorphisms.
More generally, differences in patterns of linkage disequili-
brium between populations may contribute to heterogeneity
between studies66.
The less consistent findings for A1298C, than C677T,
regarding colorectal cancer could also be because A1298C
appears to have less strong functional effects, although it
should be noted that the functional evidence is limited and
the in vitro and in vivo impact of the variant allele is not
fully resolved5,11. In analyses of 199 controls from the present
study, plasma and erythrocyte folate (measured by the micro-
biological assay) levels were significantly lower, and plasma
homocysteine levels significantly higher, in 677TT than CC
individuals, while the A1298C variant was not associated
with folate or homocysteine levels67. Neither polymorphism
was related to levels of various biomarkers of DNA stability
measured in lymphocytes, including strand breaks, misincor-
porated uracil or global methylation. The evidence from
other similar studies on MTHFR and DNA stability is incon-
sistent68–72. One reason for this may be that these studies,
and those of intake, are not assessing folate status in the rel-
evant tissue. What may be important is localised (rather than
systemic) folate depletion acting in concert with C677T11.
Current knowledge on folate status in colonic tissue is limited.
For example, the extent to which colonic folate concentrations
vary between individuals, or along the colon within a single
individual, or correlate with levels in lymphocytes or dietary
intakes, is not clear.
The significant interactions between vitamin B6 and
MTHFR genotype followed a similar pattern and had risk esti-
mates similar to those for folate. This may reflect the fact that
dietary sources for the two nutrients overlap substantially;
after adjusting for total energy intake the correlation between
folate and vitamin B6 exceeded 0·70.
Some investigators have reported an alcohol–C677T inter-
action, such that higher alcohol intake abolished the reduced
disease risk associated with the TT genotype36,54,62. The pre-
sent results suggested effect modification, but were not signifi-
cant. The median alcohol intake among consumers was lower
than the ‘high’ intake groups in previous studies (present
study, 3·9 g/d (about 0·5 units/d); Chen et al.62, $ five
drinks/week; Ma et al.36, $ one drink/d).
Most previous studies of folate and folate–MTHFR inter-
actions have been conducted in populations where intake is
relatively high, and a substantial proportion comes in the
form of folic acid. The results of the present study, undertaken
in a population with relatively low folate intake, suggest that
the role of folate metabolism in colorectal cancer aetiology
may be even more complex than previously thought.
The challenge now is to unravel this complexity. 5,10-
MTHFR irreversibly converts 5,10-methylenetetrahydrofolate
to 5-methyltetrahydrofolate, the former vital for DNA syn-
thesis and the latter key in DNA methylation. Thus, the
C677T polymorphism alters the distribution of erythrocyte
folates73, suggesting that particular folate species might
be important in colorectal cancer. The direction of the
MTHFR–colorectal cancer association – which is the oppo-
site of that expected a priori5 – suggests that the availability
of tetrahydrofolate and 5,10-methylenetetrahydrofolate may
be particularly pertinent. This is supported by a study in color-
ectal tumour tissue, which found that 677TT patients had
significantly lower concentrations of tetrahydrofolate and
5,10-methylenetetrahydrofolate74. Expansion of the evidence
on individual folate species with regard to: (1) distribution
in the diet, blood and other bodily tissues in different popu-
lations; (2) factors that influence intracellular distribution
and availability; and (3) disease risk, might help advance
understanding of folate metabolism in colorectal neoplasia
and, ultimately, shed light on carcinogenesis pathways.
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